These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 9135873)

  • 1. Correlation between changes in plasma HIV RNA levels and in plasma infectivity in response to antiretroviral therapy.
    Andreoni M; Sarmati L; Ercoli L; Nicastri E; Giannini G; Galluzzo C; Pirillo MF; Vella S
    AIDS Res Hum Retroviruses; 1997 May; 13(7):555-61. PubMed ID: 9135873
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AVANTI 2. Randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus indinavir in HIV-infected antiretroviral-naive patients.
    AIDS; 2000 Mar; 14(4):367-74. PubMed ID: 10770538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increase in neutralizing antibody titer against sequential autologous HIV-1 isolates after 16 weeks saquinavir (Invirase) treatment.
    Sarmati L; Nicastri E; el-Sawaf G; Ventura L; Salanitro A; Ercoli L; Vella S; Andreoni M
    J Med Virol; 1997 Dec; 53(4):313-8. PubMed ID: 9407377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of ritonavir and saquinavir in combination with zidovudine and lamivudine.
    Michelet C; Bellissant E; Ruffault A; Arvieux C; Delfraissy JF; Raffi F; Bazin C; Renard I; Sébille V; Chauvin JP; Dohin E; Cartier F
    Clin Pharmacol Ther; 1999 Jun; 65(6):661-71. PubMed ID: 10391672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The 48-week efficacy of once-daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy.
    Cardiello P; Srasuebkul P; Hassink E; Mahanontharit A; Samor T; Ruxrungtham K; Lange J; Cooper D; Phanuphak P
    HIV Med; 2005 Mar; 6(2):122-8. PubMed ID: 15807718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized controlled trial of a protease inhibitor (saquinavir) in combination with zidovudine in previously untreated patients with advanced HIV infection.
    Vella S; Lazzarin A; Carosi G; Sinicco A; Armignacco O; Angarano G; Andreoni M; Tambussi G; Chiodera A; Floridia M; Scaccabarozzi S; Facey K; Duncan I; Boudes P; Bragman K
    Antivir Ther; 1996 Aug; 1(3):129-40. PubMed ID: 11322246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quality of life outcomes of combination zalcitabine-zidovudine, saquinavir-zidovudine, and saquinavir-zalcitabine-zidovudine therapy for HIV-infected adults with CD4 cell counts between 50 and 350 per cubic millimeter. PISCES (SV14604) Study Group.
    Revicki DA; Moyle G; Stellbrink HJ; Barker C
    AIDS; 1999 May; 13(7):851-8. PubMed ID: 10357386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Virological efficacy and plasma drug concentrations of nelfinavir plus saquinavir as salvage therapy in HIV-infected patients refractory to standard triple therapy.
    Reiser M; Salzberger B; Stiepel A; Hoetelmans R; Diehl V; Fätkenheuer G
    Eur J Med Res; 1999 Feb; 4(2):54-8. PubMed ID: 10066640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The insufficient suppression of viral load by saquinavir hard gel is reversible: a retrospective cohort study.
    Jensen-Fangel S; Kirk O; Blaxhult A; Gerstoft J; Pedersen C; Black FT; Lundgren JD; Obel N
    HIV Clin Trials; 2001; 2(2):122-7. PubMed ID: 11590520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Viral load and burden modification following early antiretroviral therapy of primary HIV-1 infection.
    Lillo FB; Ciuffreda D; Veglia F; Capiluppi B; Mastrorilli E; Vergani B; Tambussi G; Lazzarin A
    AIDS; 1999 May; 13(7):791-6. PubMed ID: 10357377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV-1 induction-maintenance at the lymph node level: the "Apollo-97" Study.
    Lafeuillade A; Poggi C; Chadapaud S; Hittinger G; Chouraqui M; Delbeke E;
    J Acquir Immune Defic Syndr; 2001 Oct; 28(2):154-7. PubMed ID: 11588509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence and predictors of virologic failure of antiretroviral triple-drug therapy in a community-based cohort.
    Paris D; Ledergerber B; Weber R; Jost J; Flepp M; Opravil M; Ruef C; Zimmerli S
    AIDS Res Hum Retroviruses; 1999 Dec; 15(18):1631-8. PubMed ID: 10606086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity of the soft gelatin formulation of saquinavir in combination therapy in antiretroviral-naive patients. NV15355 Study Team.
    Mitsuyasu RT; Skolnik PR; Cohen SR; Conway B; Gill MJ; Jensen PC; Pulvirenti JJ; Slater LN; Schooley RT; Thompson MA; Torres RA; Tsoukas CM
    AIDS; 1998 Jul; 12(11):F103-9. PubMed ID: 9708399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma HIV-1 copy number and in vitro infectivity of plasma prior to and during combination antiretroviral treatment.
    Vella S; Galluzzo MC; Giannini G; Pirillo MF; Andreotti M; Tomino C; Fragola V; Bucciardini R; Ricciardulli D; Binelli A; Weimer LE; Floridia M
    Antiviral Res; 2000 Sep; 47(3):189-98. PubMed ID: 10974371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized double-blind trial of the addition of lamivudine or matching placebo to current nucleoside analogue reverse transcriptase inhibitor therapy in HIV-infected children: the PENTA-4 trial. Paediatric European Network for Treatment of AIDS.
    AIDS; 1998 Oct; 12(14):F151-60. PubMed ID: 9792371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV-1 viral load and CD4 cell count in untreated children with vertically acquired asymptomatic or mild disease. Paediatric European Network for Treatment of AIDS (PENTA).
    AIDS; 1998 Mar; 12(4):F1-8. PubMed ID: 9520161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid plasma virus and CD4+ T-cell turnover in HIV-1 infection: evidence for an only transient interruption by treatment.
    Stellbrink HJ; Zöller B; Fenner T; Lichtenberg G; van Lunzen J; Albrecht H; Thiele HG; Greten H
    AIDS; 1996 Jul; 10(8):849-57. PubMed ID: 8828742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of lamivudine in HIV-infected persons with prior exposure to zidovudine/didanosine or zidovudine/zalcitabine.
    Albrecht MA; Hughes MD; Liou SH; Katzenstein DA; Murphy R; Balfour HH; Para MF; Valdez H; Hammer SM;
    AIDS Res Hum Retroviruses; 2000 Sep; 16(14):1337-44. PubMed ID: 11018853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The rabbit study: ritonavir and saquinavir in combination in saquinavir-experienced and previously untreated patients.
    Churchill DR; Pym AS; Galpin S; Foxall R; Stainsby C; Clarke JR; Kaye S; Bloor S; Larder BA; Wills B; Sun E; Babiker AG; Back DJ; Weber JN
    AIDS Res Hum Retroviruses; 1999 Sep; 15(13):1181-9. PubMed ID: 10480631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group.
    Collier AC; Coombs RW; Schoenfeld DA; Bassett RL; Timpone J; Baruch A; Jones M; Facey K; Whitacre C; McAuliffe VJ; Friedman HM; Merigan TC; Reichman RC; Hooper C; Corey L
    N Engl J Med; 1996 Apr; 334(16):1011-7. PubMed ID: 8598838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.